Austin, S., Kishnani, P., Case, L., Lachmann, R., Appleby, M., Mozaffar, T., … Landy, H. (2020). Extended treatment with VAL-1221, a novel protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. In Molecular Genetics and Metabolism (Vol. 129, pp. S24–S24). Elsevier BV. https://doi.org/10.1016/j.ymgme.2019.11.033

Austin, Stephanie, Priya Kishnani, Laura Case, Robin Lachmann, Matt Appleby, Tahseen Mozaffar, Jenny Avelar, Marie Wencel, Manisha Kak, and Hal Landy. “Extended treatment with VAL-1221, a novel protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease.” In Molecular Genetics and Metabolism, 129:S24–S24. Elsevier BV, 2020. https://doi.org/10.1016/j.ymgme.2019.11.033.

Austin S, Kishnani P, Case L, Lachmann R, Appleby M, Mozaffar T, et al. Extended treatment with VAL-1221, a novel protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. In: Molecular Genetics and Metabolism. Elsevier BV; 2020. p. S24–S24.

Austin, Stephanie, et al. “Extended treatment with VAL-1221, a novel protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease.” Molecular Genetics and Metabolism, vol. 129, no. 2, Elsevier BV, 2020, pp. S24–S24. Crossref, doi:10.1016/j.ymgme.2019.11.033.

Austin S, Kishnani P, Case L, Lachmann R, Appleby M, Mozaffar T, Avelar J, Wencel M, Kak M, Landy H. Extended treatment with VAL-1221, a novel protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. Molecular Genetics and Metabolism. Elsevier BV; 2020. p. S24–S24.